Intravacc and Primrose Bio Combine Expertise for Seamless Vaccine Conjugation

• Intravacc, a CDMO specialising in infectious disease and therapeutic vaccines, partners with Primrose Bio, a biotechnology company focused on improving next-gen therapeutics manufacturing.

• Intravacc contributes technical expertise and facilities for antigen conjugation process development and GMP production, while Primrose Bio provides ultra-pure production, supply chain support, and regulatory expertise for PeliCRM197 carrier protein.

Intravacc and Primrose Bio have partnered to enhance the development and supply of conjugate vaccines, leveraging their respective strengths in vaccine development and supply chain support.

The collaboration involves Intravacc’s technical expertise and facilities, along with Primrose Bio’s technologies for improving manufacturing processes.

Intravacc contributes technical expertise, facilities, and capabilities in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines. Primrose Bio complements this with ultra-pure production, supply chain, and regulatory support for the PeliCRM197 carrier protein.

Dr. Jan Groen, CEO of Intravacc, expressed excitement about the partnership, stating, “We are excited to announce our partnership with Primrose Bio. By combining our expertise with Primrose’s cutting-edge technologies, we aim to revolutionize the landscape of conjugate vaccine development, ultimately benefiting millions worldwide.”

Dr. Helge Zieler, CEO of Primrose Bio, commented on the expanded capability of their PeliCRM197 franchise with Intravacc, creating a full-service solution for early-stage customers and partners needing vaccine conjugation development.